Boston Heart Diagnostics
Shannon Rodman-Costlow has extensive work experience in the healthcare industry. Shannon started their career as an Office Manager at Musculoskeletal Medical Specialists, INC in 2007. From there, they worked as a Dietitian Technician at The Ohio State University Wexner Medical Center from 2008 to 2009. Shannon then became a Registered Dietitian/ICU Dietitian at Genesis Healthcare System from 2010 to 2012. Following this, they worked as a Clinical Health Consultant/Registered Dietitian at Health Diagnostic Laboratory, Inc. from 2012 to 2015. Most recently, Shannon has been employed at Boston Heart Diagnostics, where they have held various roles including Registered Dietitian/Clinical Nutrition Consultant, Certified Tobacco Treatment Specialist, Sales Field Support, Sales Account Manager, and currently serves as an Area Sales Manager since March 2019.
Shannon Rodman-Costlow RD, LD, CTTS holds a Bachelor of Science (BS) degree in Nutrition Sciences from The Ohio State University. Shannon also completed a Dietetic Internship at the University of Delaware. Shannon has obtained several additional certifications, including a Certificate of Training in Adult Weight Management from the Commission of Dietetic Registration in September 2013. Moreover, they hold the title of Certified Tobacco Treatment Specialist, which they obtained from the Mayo Clinic in November 2012. Additionally, Shannon is a Registered Dietitian, certified by the Commission on Dietetic Registration, which they achieved in August 2010.
This person is not in the org chart
This person is not in any offices
Boston Heart Diagnostics
Boston Heart Lab is a healthcare company that provides cardiovascular disease (CVD) management. Through there combination of proprietary lipid testing capability, sophisticated tools, advanced therapy guidelines, and patient support services, they are providing physicians, patients, and pharmaceutical companies with viable disease management.Unlike other lipid testing companies that are focused on the primary screening market for CVD, their proprietary testing technology allows for the ongoing monitoring of a patient's disease and precise determination of the most appropriate pharmaceutical alternatives. They can provide unique, personalized treatment options to patients with dyslipidemia to determine the efficacy of lipid adjusting drugs in most cases within the first 6 weeks of treatment. Competing methods usually need 6 months.